Enzyme-Controlled Nanodevice for Acetylcholine-Triggered Cargo Delivery Based on Janus Au-Mesoporous Silica Nanoparticles by Llopis-Lorente, Antoni et al.
 Document downloaded from: 
 

























Llopis-Lorente, A.; Díez, P.; De La Torre-Paredes, C.; Sanchez, A.; Sancenón Galarza, F.;
Aznar, E.; Marcos Martínez, MD.... (2017). Enzyme-Controlled Nanodevice for
Acetylcholine-Triggered Cargo Delivery Based on Janus Au-Mesoporous Silica
Nanoparticles. Chemistry - A European Journal. 23(18):4276-4281.
https://doi.org/10.1002/chem.201700603
https://doi.org/10.1002/chem.201700603
John Wiley & Sons
"This is the peer reviewed version of the following article: Llopis-Lorente, Antoni, Paula Díez,
Cristina de la Torre, Alfredo Sánchez, Félix Sancenón, Elena Aznar, María D. Marcos,
Paloma Martínez-Ruíz, Ramón Martínez-Máñez, and Reynaldo Villalonga. 2017.  Enzyme-
Controlled Nanodevice for Acetylcholine-Triggered Cargo Delivery Based on Janus Au-
Mesoporous Silica Nanoparticles.  Chemistry - A European Journal 23 (18). Wiley: 4276 81.
doi:10.1002/chem.201700603, which has been published in final form at
https://doi.org/10.1002/chem.201700603. This article may be used for non-commercial
purposes in accordance with Wiley Terms and Conditions for Self-Archiving."





Enzyme-Controlled Nanodevice for Acetylcholine-Triggered 
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Abstract: This work reports a new gated nanodevice for 
acetylcholine-triggered cargo delivery. We prepared and 
characterized Janus Au-mesoporous silica nanoparticles 
functionalized with acetylcholinesterase on the Au face and with 
supramolecular β-cyclodextrin:benzimidazole inclusion complexes 
as caps on the mesoporous silica face. The nanodevice is able to 
selectively deliver the cargo in the presence of acetylcholine via 
enzyme-mediated acetylcholine hydrolysis, locally lowering the pH 
and opening the supramolecular gate. Given the key role played by 
ACh and its relation with PD and other nervous system diseases, we 
believe that these findings could help design new therapeutic 
strategies. 
Acetylcholine (ACh) is an essential neurotransmitter that 
operates in the central and peripheral nervous system.[1] It acts 
as a messenger from neurons to muscle cells producing muscle 
contraction, and is involved in attention, memory and learning.[2] 
Research has related ACh abnormal levels with 
neurodegenerative disorders,  such as Parkinson’s disease (PD), 
Alzheimer’s disease, multiple sclerosis and Huntington’s 
disease.[3] In PD, diminished striatal dopaminergic activity leads 
to increased ACh release by interneurons.[4] In this context, 
disruption of the acetylcholine-dopamine balance leads to PD 
symptoms, which include tremor, hypokinesia, muscular rigidity 
and neuropsychiatric disorders, including depression, fatigue, 
and speech and memory problems.[5] Drug therapy in PD aims 
to correct the imbalance between dopamine and ACh,[6] as 
accomplished by oral administration of: (i) levodopa, a dopamine 
precursor;[7] (ii) dopamine agonists that activate dopamine 
receptors;[8] and (iii) anticholinergics, used to lower ACh levels.[9] 
However, many adverse side effects (e.g. dyskinesia, motor 
fluctuations, psychosis and drug-resistance) are associated with 
these drugs and impact PD patients’ quality of life.[10] In order to 
find new ways to treat PD, an appealing approach is to design 
nanocarriers able to deliver a certain drug in regions with high 
ACh levels. 
From another point of view, much interest has been shown 
in recent years in the development of stimuli-responsive 
nanomaterials for drug delivery given their potential application 
in nanomedicine.[11] Among the various potential nanocarriers, 
silica mesoporous supports (SMS) are especially appealing 
because of their unique properties, such as high loading 
capacity, easy functionalization, low cost and biocompatibility.[12] 
In addition, one interesting characteristic of SMS is the 
possibility of functionalizing the external surface with molecular 
and/or supramolecular ensembles that act as molecular gates. 
These gated solids show no cargo release, but can deliver the 
payload in response to certain external stimuli, thus minimizing 
therapy-derived side effects. In line with this, SMS that are 
responsive to different stimuli, e.g. light, temperature, magnetic 
fields, enzymes, DNA, redox reactions and pH, have been 
developed.[13] However, very few examples of gated SMS that 
can deliver their cargo in the presence of target small molecules 
of biological importance have been reported.[13b] 
In this area of gated chemistry we recently reported the 
design of more sophisticated nanodevices for delivery 
applications based on Janus nanoparticles with Au and 
mesoporous silica (MS) on opposite faces.[14] This allows the 
inclusion of responsive ensembles anchored to the pore outlets 
of the mesoporous face, and also a “control unit” on the Au face 
that directs the operation (cargo delivery) of the gated material. 
 Given the importance of ACh in nervous system diseases 
such as PD, the need for developing better therapies, and given 
our interest in designing gated hybrid materials,[15] we report 
herein the preparation of an acetylcholinesterase-controlled 
nanodevice based on Janus-type Au-mesoporous silica 
nanoparticles. Scheme 1 illustrates the design of the system. 
Enzyme acetylcholinesterase is immobilized on the Au face of 
the Janus support, which acts as the “control unit”. The MS face 
is loaded with the cargo (e.g. [Ru(bpy)3]Cl2) and is functionalized 
with a pH-responsive β-cyclodextrin (β-CD)-benzimidazole 
supramolecular nanovalve. The Au side acts as an “effector” in 
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which acetylcholinesterase monitors the presence of over-
expressed ACh and induces cargo delivery. In particular, it is 
expected that the hydrolysis of ACh by the enzyme to give 
choline and acetic acid will induce a local decrease in pH, which 
will result in the protonation of benzimidazole, the rupture of β-
CD-benzimidazole ensemble and cargo release. Such a 
nanodevice may play a double role when reaching regions with 
high ACh concentrations, such as neuromuscular junctions or 
the striatum in PD patients: (i) local cargo delivery that would 




Scheme 1. Representation of the performance of nanodevice S3. The “control 
unit” (Au face) is functionalized with acetylcholinesterase, which directs the 
cargo delivery from the mesoporous face in the presence of ACh. 
In order to prepare the nanodevice, we first synthesized 
MS nanoparticles by hydrolysis and condensation of tetraethyl 
orthosilicate in basic media using n-cetyltrimethylammonium 
bromide as a template. Surfactant removal by calcination yielded 
the starting mesoporous support (MCM-41). Gold nanoparticles  
were synthesized by reduction of Au (III) with sodium citrate, 
according to the Turkevich-Frens method.[16] Then MCM-41 
nanoparticles were confined at a Pickering emulsion using 
paraffin wax to achieve its partial functionalization with (3-
mercaptopropyl)triethoxysilane, to which Au nanoparticles were 
attached. Next we dissolved paraffin wax in CHCl3 to finally 
obtain Janus Au-MS nanoparticles (S1). Afterward, mesoporous 
scaffold pores were loaded with [Ru(bpy)3]Cl2 and the external 
surface was functionalized with (3-iodopropyl)trimethoxysilane. 
Then a nucleophilic substitution reaction between the grafted 
iodopropyl moieties and benzimidazole yielded solid S2. The 
pores of the S2 nanoparticles were capped with a pH-sensitive 
supramolecular nanovalve by stirring the solid with β-CD in 
water, which led to the formation of inclusion complexes 
between the benzimidazole groups and β-CD. Finally, 
acetylcholinesterase, previously modified on its glycosylation 
chains with thiol groups,[17] was covalently immobilized on the Au 
face by incubation in 50 mM sodium phosphate buffer (pH 7.5) 
at 0ºC, which resulted in the final nanodevice S3 (see 
Supporting Information for further details). 
 
 
Figure 1. Top: Representative (A) TEM and (B) SEM images of Janus Au-MS 
nanoparticles (S1) Down: PXRD of (a) calcined MCM-41 and (b) final 
nanodevice S3 at low (left) and high (right) angles. 
We followed standard procedures to characterize the 
prepared solids (see Supporting Information). Transmission 
electron microscopy (TEM) confirmed both the mesoporous 
morphology of the MCM-41 nanoparticles (average diameter: 
70±15 nm) and the presence of Au nanoparticles (average 
diameter: 21±4 nm) in Janus colloids (S1, see Figure 1A). 
Additionally, SEM images of the colloids were also acquired 
where gold nanoparticles clearly appear as bright dots (see 
Figure 1B). Powder X-ray diffraction (PXRD), carried out on the 
starting MCM-41 nanoparticles, showed the (100) low-angle 
reflection peak that is characteristic of these mesoporous 
materials. Preservation of the (100) peak in the following solids 
(S1, S2, S3) (see Figure SI-2) clearly confirmed that the dye 





loading and chemical modifications processes did not damage 
the 3D mesoporous structure. The diffraction pattern at a high 
angle for all the Janus colloids showed the cubic gold 
characteristic (111), (200), (220), and (311) peaks, which 
confirmed the presence of gold nanocrystals.[18] From 
thermogravimetric and elemental analyses, we determined the 
contents of [Ru(bpy)3]Cl2 and benzimidazole on S2 to be 0.162 g 
and 0.105 g per gram of nanoparticles, respectively. For 
nanodevice S3, we determined the amount of immobilized 
acetylcholinesterase as 93 U·g-1, that corresponds to 3.4 mg g-1 
of S3 (see Figure SI-7). We also calculated the BET specific 
surface values, pore volumes and pores sizes from the N2 
adsorption-desorption isotherms (summarized in Table SI-1). 
The solids were also characterized by FT-IR analysis (see 
Figure SI-5). Further, dynamic light scattering (DLS) studies 
under physiological conditions (PBS, pH 7.5) were carried out on 
the materials (see Table SI-2). Functionalization with 
benzimidazole moieties reduced the zeta potential of the 
nanoparticles S2 (-6.6 mV) compared to calcined MCM-41 (-
21.5 mV) and Janus colloids S1 (-12.5 mV). For the final 
nanodevice S3, the surface charge increased (-14.9) compared 
to S2 as a consequence of enzyme functionalization and β-
cyclodextrin capping. In addition, the hydrodynamic diameter for 
each material was also determined. An increase after each 
functionalization step was observed which resulted in a 
hydrodynamic diameter of 195 nm for the final S3 nanodevice 
(hydrodynamic diameter for MCM-41, S1 and S2 was 91.2, 
141.8 and 164.2 nm respectively). 
In order to test the capacity of the capped Janus 
nanoparticles to deliver the cargo, we brought S3 to a 
concentration of 0.9 mg·mL-1 in water at pH 7.5 (20 mM Na2SO4) 
in the absence and presence of ACh (1 mM). We took aliquots 
at scheduled times, centrifuged to remove nanoparticles, and we 
evaluated cargo release by measuring the emission band of 
[Ru(bpy)3]Cl2 at 595 nm (λexc = 453 nm). Figure 2 shows the 
payload delivery kinetics. In the absence of ACh, S3 is tightly 
capped and dye release is negligible. However, presence of 
ACh induced pore opening and a subsequent remarkable cargo 
delivery in under 5 minutes. We attributed the response in the 
presence of ACh to the “detection” of this neurotransmitter by 
acetylcholinesterase (effector) in the “control unit”, which 
triggered cargo release from the MS nanocarrier. 
Acetylcholinesterase catalyzed the hydrolysis of ACh to choline 
and acetic acid (pKa = 4.75). Acetic acid induced the protonation 
of benzimidazole groups (pKa = 5.55)[19] on the MS face and the 
dethreading of the supramolecular nanovalve, which finally 
resulted in cargo delivery. Testing the response of the β-
cyclodextrin-capped solid (without enzyme) in the presence of 
ACh demonstrated the crucial role played by the enzyme in the 
“control unit”. In this case, no payload delivery took place. 
 
Figure 2. Normalized cargo release from S3 determined by measuring 
[Ru(bpy)3]Cl2 fluorescence at 595 nm (λexc = 453 nm) versus time in water at 
pH 7.5 (20 mM Na2SO4) in the absence (curve a) and presence (curve b) of 
ACh 1 mM. Error bars from three independent experiments. 
The second step tested the response of solid S3 in the 
presence of some other important neurotransmitters, such as 
serotonin (5-HT), dopamine (DA), norepinephrine (NE), glycine 
(Gly), γ-aminobutyric acid (GABA), aspartic acid (Asp) and 
glutamic acid (Glu). Figure 3a shows the release of ruthenium 
dye upon the addition of these neurotransmitters (1 mM) to 
suspensions of S3 (0.9 mg·mL-1). These chemicals were unable 
to trigger cargo release in S3, which opened selectively in the 
presence of ACh.  
In another step we studied the response of S3 according to 
ACh concentration (see the results in Figure 3b). A linear dye 
release occurred within the 10-5-10-2 mol·L-1 ACh concentration 
range. From the calibration curve, we calculated a limit of 
detection (LOD) to be 1.5 × 10-5 mol·L-1. It is noteworthy that S3 
did not respond to concentrations lower than 10 µM. When 
compared this data with the ACh concentrations found in the 
body and reported in the literature (see Table SI-4), this 
suggested that S3 would remain capped at ACh levels found in 
human blood (9 nM),[20] but would release its cargo at regions 
with higher ACh concentrations. For instance, ACh 
concentration in synaptic vesicles is estimated to be  100 mM[21] 
and in neuromuscular junctions and synaptic clefts ACh levels 
have been reported to be 3-0.5 mM[21] under normal conditions 
and might increase in PD patients.[4]  Although, the ACh 
concentration reached just upon presynaptic release is not 
precisely known, several studies have reported ACh 
concentrations in the striatum (which is the target region for 
levodopa and other PD drugs) to be 30-50 µM[22]. In other brain 
regions such as the hippocampus and frontal cortex, ACh levels 
are also higher (ca. 7 and 3.75 mM respectively)[23] suggesting 
that S3 would also deliver the cargo in these regions. Despite 
the fact that the road from these results to the in vivo use of 
similar nanodevices remains long and uncertain, these results 
suggested S3 or similar nanodevices could be suitable drug 
release systems for the treatment of diseases such as PD. 






Figure 3. a) Normalized cargo release from S3 in the presence of different 
neurotransmitters at 1 mM. b) Normalized cargo release after 5 min according 
to ACh concentration. Error bars from three independent experiments. 
We ultimately aimed to demonstrate that the Janus capped 
system can be used to deliver cargo in the presence of ACh in a 
biological complex medium. In particular for these experiments, 
we prepared similar nanoparticles to S3, but loaded with 
cytotoxic doxorubicin (Doxo) (solid S4, see Supporting 
Information). We did spectrophotometric studies to calculate the 
amount of Doxo loaded on S4 that was found to be 0.035 g per 
gram of solid. The release in vitro experiments showed that S4 
(0.9 mg·mL-1) remained capped for at least 24 h, but Doxo 
release was substantial in the presence of ACh (see Figure 4A). 
Next as proof of concept, we added 100 µg·mL-1 of S4 to the 
culture media of human cervix adenocarcinoma (HeLa) cells, 
further incubated alone or in the presence of ACh (thus 
simulating a biological region with overexpressed ACh). We 
studied Doxo delivery from S4 by means of cell viability WST-1 
assays and confocal microscopy by tracking Doxo-associated 
fluorescence. Figure 4B shows the cell viability results after 24 h. 
These experiments clearly indicated the reduction in viability of 
the HeLa cells treated with S4 in a medium that contained ACh 
(50% of cells were dead after 24 h). We ascribed this effect to 
the ACh-induced opening of S4 nanoparticles with the 
subsequent Doxo release. In contrast, the cells treated with S4 
in an ACh-free medium remained alive, which indicated that S4 
nanoparticles were not toxic for HeLa cells in the absence of 
ACh. We also observed a clear S4 concentration-dependent 
decrease of living cells in the presence of ACh (see Figure SI-8).  
 
 
Figure 4. A) Kinetics of Doxo release from S4 (0.9 mg·mL-1) in water at pH 7.5 
(20 mM NasSO4) in the absence (a) and presence (b) of ACh (10 mM), 
estimated by measuring fluorescence at 557 nm (λexc = 495 nm). B) Cell 
viability test for S4. Results plotted from left to right for the control experiment, 
incubation with ACh (40 mM), incubation with S4 (100 µg·mL-1), and 
incubation with both ACh (40 mM) and S4 100 (µg·mL-1). Error bars for three 
independent experiments. C) Controlled release of Doxo from S4 (100 µg·mL-
1) in HeLa cells culture media examined by confocal microscopy for (a) the 
control experiment, (b) incubation with S4 and (c) incubation with S4 and ACh.  
 Furthermore, the confocal microscopy images of the HeLa 
cells (Figure 4C) incubated with S4 showed clear Doxo-related 
fluorescence (green) in the cellular cytosolic compartment. In 
contrast, we observed negligible fluorescence in the cells 
incubated with S4 in ACh-free media. This meant that the 
nanocarrier was unable to release its cargo under these 
conditions. Remarkably, despite the presence of a large amount 





of cellular metabolites and proteins in the cell media, which 
could have compromised the performance of S4, the results 
indicated optimal functional behavior for the nanoparticles that 
delivered the cargo in the presence of ACh. 
 In conclusion, we have designed, synthesized and 
characterized a new enzyme-controlled nanocarrier for ACh-
triggered cargo delivery. In particular, the functional capped solid 
is based on Janus-type nanoparticles functionalized with 
acetylcholinesterase on the Au-face and a supramolecular pH-
responsive nanovalve on the MS surface. In the presence of 
ACh, the acetylcholinesterase enzyme hydrolyses the 
neurotransmitter and induces the dethreading of the nanovalve 
and cargo release. We observed fast cargo delivery kinetics 
(less than 5 min) and a selective response to ACh among other 
neurotransmitters tested. The nanocarrier responded to ACh 
concentrations higher than 10 µM, which is below the ACh blood 
levels and within the range of concentrations found in 
neuromuscular junctions and in the striatum, the target region for 
PD drugs. The capped Janus nanoparticles displayed selective 
ACh-dependent cargo delivery even in a biological complex 
medium (HeLa cells). If we bear in mind the key role played by 
ACh and its relation with PD and other nervous system diseases, 
we believe that these findings could help design new therapeutic 
strategies. We also expect the possibility of combining different 
molecular gates on the MS face with distinct enzyme-based 
effectors on the Au surface to inspire the development of new 
advanced delivery systems that could selectively deliver their 
cargo in the presence of target small molecules of biological 
importance. 
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We prepared and characterized Janus 
Au-mesoporous silica nanoparticles 
functionalized with 
acetylcholinesterase on the Au face 
and with supramolecular β-
cyclodextrin:benzimidazole inclusion 
complexes as caps on the 
mesoporous silica face. The 
nanodevice is able to selectively 
deliver cargo in the presence of 
acetylcholine via enzyme-mediated 
acetylcholine hydrolysis, locally 
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